Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 3, 1998, Pages 237-245

  Andriulli, A ^a   Leandro, G ^b   Clemente, R ^a   Festa, V ^a   Caruso, N ^a   Annese, V ^a   Lezzi, G ^a   Lichino, E ^b   Bruno, F ^a   Perri, F ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GABEXATE MESILATE; OCTREOTIDE; SOMATOSTATIN;

ACUTE PANCREATITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; HUMAN; MEDICAL INFORMATION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK;

ACUTE DISEASE; ANTICOAGULANTS; CLINICAL TRIALS; GABEXATE; HORMONE ANTAGONISTS; HORMONES; HUMANS; OCTREOTIDE; PANCREATITIS; SOMATOSTATIN; STATISTICS; TREATMENT OUTCOME;

EID: 15144354769     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00295.x     Document Type: Article

References (42)

1. Steinberg WM, Schlesselman SH. Treatment of acute pancreatitis: comparison of animal and human studies. Gastroenterology 1987; 93: 1420-7.
2. Carballo I, Dominguez E, Fernandez-Calvet I, Martinez-Pancorba C, Garcia H, De la Marena J. Is somatostatin useful in the treatment of acute pancreatitis? A meta analysis. Digestion 1991; 49: 12-13.
3. Messori A, Rampazzo R, Scroccaro G, et al. Effectiveness of gabexate mesilate in acute pancreatitis. A meta-analysis. Dig Dis Sci 1995; 40: 734-8.
4. Cimarelli S, Anglesio V, Giovanelli A, Bavuso D, L'uso della somatostatina nelle pancreatiti acute di origine biliare. Minerva Med 1987; 78: 483-7.
5. Choi TK, Mok F, Zhan WH, Fan ST, Lai ECS, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomized controlled trial. Gut 1989; 30: 223-7.
6. Russello D, Puleo S, Li Destri G, Scuderi M, Latteri F. Ruolo della somatostalina e della nutrizione parenterale nel trattamento delle pancreatiti acute. Minerva Chir 1989; 44: 843-7.
7. D'Amico D, Favia G, Biasiato R, et al. The use of somatostatin in acute pancreatitis - results of a multicenter trial. Hepatogastroenterology 1990; 37: 92-8.
8. Gjorup I, Roikjaer O, Andersen B, et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surgery 1992; 175: 397-400.
9. Luengo L, Vincente V, Gris F, et al. Influence of somatostatin in the evolution of acute pancreatitis. Int J Pancreatol 1994; 15: 139-44.
10. Tanaka N, Tsuchaiya R, Ishii K. Comparative clinical study of FOY and Trasylol in acute pancreatitis. Adv Exp Med Biol 1979; 120: 367.
11. Freise J, Melzer P, Schmidt FW, Horbach L. Gabexat mesilat in der Behandlung der akuten Pankreatitis Ergebnisse der hannoverschen multizentrischen Doppleblindstudie. Z Gastroenterol 1986; 24: 200-11.
12. Young CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698-700.
13. Valderama R, Perez-Mateo M, Navarro S, Vaquez N, Adrian M, Estruch J. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51: 65-70.
14. Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Dig Dis Sci 1993; 38: 644-7.
15. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 1995; 181: 121-4.
16. Mitrovic M, Sijarid A, Tadoravim M, Karameskovie A. Acute pancreatitis treated with somatostatin. The double-blind study. Proceedings of the Gastrosurgical Club Madrid. 1993; pp. 1444-5.
17. Usadel KH, Uberla KK, Leuschner U. Treatment of acute pancreatitis with somatostatin: results of the multicenter double-blind trial (APTS-study). Dig Dis Sci 1985; 30: A32(Abstract).
18. Zuniga J, Garcia L, Ortiz J, Pajares M. Estudio de la eticacia del tratamiento con somatostatina en pancreatitis agudas graves. Proc. de las XIV Jornadas Hispano-Francesas de Gastroenterologic. Burgos. October 1987: pp. 39-40.
19. Sanchez D, Sanchez A, Zurdo JR, Arriaza R, Chimpen V, Portugal A. Pancreatitis aguda. Estudio clinico y terapeutico. Valoracion de la eticacia de la somatostatina. An Med Inter (Madrid) 1988; 27(Suppl. 3): 40A(Abstract).
20. Schondube F, Klempa I, Baca I, Menzel J. Nekrotisierende pancreatitis - ein beitrang zur stadiengerechten operativen therapie. Österr Gesell Chir Larz. June 1987 (thesis).
21. Goebell H and the German Pancreatitis study group. Multicenter double-blind study of gabexate-mesilate (FOY), given intravenously in low dose in acute pancreatitis. Digestion 1988; 40(Abstract): 83.
22. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG and the German Pancreatitis study group. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104: 1165-70.
23. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs. aprotinin in human acute pancreatitis (GA.ME.P.A.). Int J Pancreatol 1993; 14: 117-23.
24. O'Hair DP, Hoffman RG, Schroeder H, Wilson SP. Octreotide in the treatment of acute pancreatitis. Gastroenterology 1993; 104: A326(Abstract).
25. Fiedler F, Keim V, Bender HJ. Is octreotide of therapeutic value in the treatment of acute necrotizing pancreatitis? Gastroenterology 1994; 106: A292(Abstract).
26. McKay C, Baxter JN, Imrie CW. Octreotide in acute pancreatitis: a randomized controlled trial. Br J Surg 1994; 81: 1799-826.
27. The Acute Pancreatitis Italian Study Group. Octreotide in the treatment of acute pancreatitis. Digestion 1994; 55: A165 (Abstract).
28. Karatapanis S, Georgopoulos S, Kassl E, Zafiris I, Filis H, Artikis V. Octreotide in the treatment of acute pancreatitis. Gut 1995; 37: A186(Abstract).
29. Guarner L, Puig-Divi V, Borruel N, Alvarez A, Malagelada JR. Therapeutic usefulness of high dose octreotide in the management of the severe necrotizing pancreatitis. Gastroenterology 1995; 108(Abstract): 357.
30. Uhl W, Malfertheiner P, Adler G, et al. A randomized controlled multicentric trial on the role of octreotide in human acute pancreatitis. Gastroenterology 1997; 112: A488(Abstract).
31. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Henszel variance consistent in both sparse data and large strata limiting models. Biometrics 1986; 42: 311-23.
32. Rosenthal R. The 'file-drawer problem' and tolerance for null results. Psychol Bull 1979; 86: 638-41.
33. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer 1986; 58: 1378-86.
34. Trapnell JE, Rigley CC, Talbot CH, Duncan EH. A controlled trial of trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61: 177-82.
35. Renner IG, Savage WT, Pantoja JL, Renner JV. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. Dig Dis Sci 1985; 30: 1005-18.
36. Morgan JS, Groszman RJ. Somatostatin in portal hypertension. Dig Dis Sci 1989; 34(Suppl 3): 405-475.
37. Baxter JN, Jenkins SA, Day DW, Shields R. Effects of a somatostatin analogue on hepatic and splenic reticuloendothelial function in rats. Br J Surg 1985; 72: 1005-8.
38. Eliakin R, Karmili F, Okon E, Rachmiliewitz D. Octreotide effectively decreases mucosal damage in experimental colitis. Gut 1993; 34: 264-9.
39. D'Amico G, Pagliaro L, Boseh J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
40. Kivilaakso E, Valtonen VV, Malkamaki M, et al. Endotoxaemia and acute pancreatitis: correlation between the severity of the disease and the anti-bacterial common antigen antibody titre. Gut 1984; 25: 1065-70.
41. Banks RE, Evans SW, Alexander D. Is portal pancreatitis a consequence of excessive leucocyte stimulation? The role of tumor necrosis factor. Cytokine 1990; 3: 1-6.
42. Curley PJ, McMahon MJ, Lancaster F. Reduction in circulating levels of CD-4 positive lymphocytes in acute pancreatitis: relationship to endotoxin interleukin 6 and disease severity. Br J Surg 1993; 80: 1312-15.